Glutathione Induces Keap1 S-Glutathionylation and Mitigates Oscillating Glucose-Induced β-Cell Dysfunction by Activating Nrf2

Xiufang Chen,Qian Zhou,Huamin Chen,Juan Bai,Ruike An,Keyi Zhang,Xinyue Zhang,Hui An,Jitai Zhang,Yongyu Wang,Ming Li,Chen,Zhou,Chen,Bai,An,Zhang,Zhang,An,Zhang,Wang,Li

DOI: https://doi.org/10.3390/antiox13040400

IF: 7.675

2024-03-28

Antioxidants

Abstract:Glutathione (GSH), a robust endogenous antioxidant, actively participates in the modulation of the redox status of cysteine residues in proteins. Previous studies have indicated that GSH can prevent β-cell failure and prediabetes caused by chronic oscillating glucose (OsG) administration. However, the precise mechanism underlying the protective effect is not well understood. Our current research reveals that GSH is capable of reversing the reduction in Nrf2 levels, as well as downstream genes Grx1 and HO-1, in the islet β-cells of rats induced by chronic OsG. In vitro experiments have further demonstrated that GSH can prevent β-cell dedifferentiation, apoptosis, and impaired insulin secretion caused by OsG. Additionally, GSH facilitates the translocation of Nrf2 into the nucleus, resulting in an upregulation of Nrf2-targeted genes such as GCLC, Grx1, HO-1, and NQO1. Notably, when the Nrf2 inhibitor ML385 is employed, the effects of GSH on OsG-treated β-cells are abrogated. Moreover, GSH enhances the S-glutathionylation of Keap1 at Cys273 and Cys288, but not Cys151, in OsG-treated β-cells, leading to the dissociation of Nrf2 from Keap1 and facilitating Nrf2 nuclear translocation. In conclusion, the protective role of GSH against OsG-induced β-cell failure can be partially attributed to its capacity to enhance Keap1 S-glutathionylation, thereby activating the Nrf2 signaling pathway. These findings provide novel insights into the prevention and treatment of β-cell failure in the context of prediabetes/diabetes, highlighting the potential of GSH.

biochemistry & molecular biology,chemistry, medicinal,food science & technology

What problem does this paper attempt to address?

### The Problem the Paper Attempts to Solve

This paper aims to explore how glutathione (GSH) activates the Nrf2 signaling pathway by promoting the S-glutathionylation of Keap1, thereby alleviating oscillating glucose (OsG)-induced β-cell dysfunction. Specifically:

1. **Background and Problem**:
- Research has found that long-term oscillating glucose (LOsG) leads to β-cell dysfunction and impaired insulin secretion, which can trigger a pre-diabetic state.
- Previous studies have shown that exogenous supplementation of glutathione (GSH) can prevent β-cell damage caused by oscillating glucose, but the specific mechanism remains unclear.

2. **Research Objectives**:
- To investigate how GSH activates the Nrf2 signaling pathway by promoting the S-glutathionylation of Keap1, thereby reducing the damage to β-cells caused by oscillating glucose.
- To study whether GSH can restore β-cell function under oscillating glucose conditions through this mechanism.

3. **Main Findings**:
- GSH can reverse the decrease in Nrf2 levels and the reduced expression of its downstream genes Grx1 and HO-1 caused by oscillating glucose.
- GSH promotes the translocation of Nrf2 into the nucleus, upregulating the expression of Nrf2 target genes such as GCLC, Grx1, HO-1, and NQO1.
- GSH enhances the S-glutathionylation of Keap1 at Cys273 and Cys288 sites in β-cells treated with oscillating glucose, causing Nrf2 to dissociate from Keap1 and further activating the Nrf2 signaling pathway.

In summary, this paper reveals that GSH activates the Nrf2 signaling pathway by enhancing the S-glutathionylation of Keap1, thereby protecting β-cells from oscillating glucose-induced dysfunction. This provides new insights for the prevention and treatment of pre-diabetes.